Nexentis Subsidiary MitoCareX Unveils Optimized Hit Molecule with Improved Drug Properties
MitoCareX Bio, a wholly owned subsidiary of Nexentis Technologies, generated an optimized hit molecule with substantially improved pharmaceutical properties using the MITOLINE® algorithm platform. The small-molecule candidate targets a mitochondrial SLC25 carrier protein for hard-to-treat cancers and inflammatory metabolic diseases and now advances toward preclinical lead optimization.
1. Optimization Milestone Achieved
MitoCareX Bio completed systematic medicinal chemistry optimization of its initial hit compound by March 31, 2026, yielding an optimized hit molecule with enhanced metabolic stability and superior drug-like properties compared to the program’s first lead.
2. MITOLINE® Algorithm Enables Discovery
The U.S. trademark-registered MITOLINE® algorithm generated reliable 3D structural models of the mitochondrial SLC25 carrier protein, overcoming the absence of experimental structures and powering virtual screening to identify and refine hit candidates.
3. Target Profile and Market Opportunity
The novel small-molecule candidate is designed to modulate a mitochondrial SLC25 carrier protein, addressing high-unmet-need indications in oncology and inflammatory metabolic diseases, where the cancer therapy market is projected to grow from $270 billion to $447 billion by 2031 and the anti-inflammatory segment from $129 billion to $185 billion.
4. Path to Preclinical Lead Development
Following this milestone, MitoCareX is advancing toward lead molecule nomination and entry into preclinical trials, positioning Nexentis to progress its mitochondrial drug discovery program into the next development phase.